Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.
about
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study GroupPrognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic SyndromeReport on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.Effectiveness of azacitidine in higher-risk myelodysplastic syndromes.The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment.Excess mortality in the myelodysplastic syndromes.Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States.Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatmentHypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing landscape or a small dent?More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes.Myelodysplastic syndromes (MDS) in regular care in Germany - the oldest patients come to the fore.Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
P2860
Q31163049-37C3771F-ACCA-4457-B73C-269634034610Q36185741-46C4944B-CED2-40C3-9D49-4226F6A7FA0CQ38411523-76E72416-40A7-4042-A051-D568D6AF3F37Q38651923-392ACD1B-69EB-4D00-A6F5-8D9A78B24443Q38837834-446E81E8-ADC0-4FCC-A3A1-87C9E0EDDA24Q39752170-D7AD5316-3C20-4E34-ADA9-61DA66DFB045Q40095812-4DF3FF7C-8C4A-4B8D-8590-884A0C836B16Q40470007-47E6CD9C-6061-4CBC-BDB1-177E7406FB48Q40572555-74AE9994-97D5-40E1-851F-435F770D403DQ40608642-4675619A-E333-438C-B3E1-C86D0AAE50BBQ42837959-84E35519-DF50-4AA5-BCB8-CD6C4F38CCC7Q49789581-C9B42357-AC05-4390-925B-756273CD4359Q50052465-B5A582AD-A488-4F2E-AC8A-78E1403EF4E4Q50072054-A6CA363A-47BC-4792-B8F5-B8474344F388Q55035043-FB146CC3-A0AB-4EB4-8979-F61FA2662CC0
P2860
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Effectiveness of azacitidine i ...... lts from the Spanish registry.
@en
type
label
Effectiveness of azacitidine i ...... lts from the Spanish registry.
@en
prefLabel
Effectiveness of azacitidine i ...... lts from the Spanish registry.
@en
P2093
P2860
P50
P356
P1433
P1476
Effectiveness of azacitidine i ...... ults from the Spanish registry
@en
P2093
B Nomdedeu
C del Cañizo
J Sánchez-García
L Benlloch
M T Ardanaz
P2860
P2888
P304
P356
10.1038/LEU.2015.115
P577
2015-05-06T00:00:00Z
P5875
P6179
1021869837